Macroleuco 300

Contents: Filgrastim

Preparation: 300mcg/1.2 mL

Packing: 10 vials

Indication/Uses: Used in the mobilization of peripheral blood progenitor cells for autologous peripheral blood stem cell transplantation.Used for the treatment of congenital neutropenia. Used for the treatment of Idiopathic or cyclic neutropenia. Used for the treatment of HIV infection and persistent neutropenia. Used for the treatment chemotherapy-induced neutropenia. Used in bone marrow transplantation.

Dosage/Direction for Use: For the stem cell mobilization of peripheral blood progenitor cells, use 10 mcg/kg/day as a single injection or by continuous infusion for 4 to 7 days until the last leukapheresis procedure.If it is given after myelosuppressive chemotherapy, administer 5 mcg/kg daily by injection. It is to be given from the first day after chemotherapy completion until expected neutrophil nadir is passed and the neutrophil count has returned to normal range so that leukapheresis can be performed. For the treatment of congenital neutropenia, use 12 mcg/kg/day.For the treatment of idiopathic or cyclic neutropenia, use 5 mcg/kg/day.In the treatment of HIV infection and persistent neutropenia, use an initial dose of 1 mcg/kg/day and increase up to 4 mcg/kg/day until the neutrophil count is normalized. For maintenance, the dosage should be 300 mcg/day, with a maximum dose of 4 mcg/kg/day.For the parenteral administration in the treatment of chemotherapy-induced neutropenia, use 5 mcg/kg/day through subcutaneous injection, as a continuous intravenous or subcutaneous infusion, or as a daily intravenous infusion over 15 to 30 minutes, starting not less than 24 hours after the last antineoplastic dose. Continue treatment until the neutrophil count has stabilized within the normal range, which may take up to 14 days or more.For the parenteral administration In bone marrow transplantation, use 10 mcg/kg/day by intravenous infusion over 30 minutes or 4 hours or continuous intravenous or subcutaneous infusion over 24 hours. Adjust according to the patient's response.

Special Precaution: Extra caution should be taken by patients with the following conditions:Premalignant or malignant myeloid condition, Sickle-cell disease, Osteoporotic bone disease, Fluid retention or heart failure.Pregnancy and lactation.

Adverse Reactions

  • Musculoskeletal pain
  • Bone pain
  • Hypersensitivity reactions
  • Splenic enlargement
  • Hepatomegaly
  • Thrombocytopenia
  • Anaemia
  • Epistaxis
  • Headache
  • Nausea
  • Vomiting
  • Diarrhoea
  • Urinary abnormalities (dysuria, proteinuria, and haematuria)
  • Osteoporosis
  • Exacerbation of rheumatoid arthritis
  • Transient decrease in blood glucose
  • Raised uric acid
  • Cutaneous vasculitis
  • Transient hypotension
  • Potentially fatal pulmonary infiltrates leading to respiratory failure or acute respiratory distress syndrome

Storage: Refrigerate at 2° to 8°C.Do not freeze.